Evolent Health (EVH) Given Consensus Rating of “Buy” by Analysts

Shares of Evolent Health (NYSE:EVH) have been given a consensus rating of “Buy” by the sixteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation and twelve have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $25.33.

A number of analysts have weighed in on the company. Jefferies Group set a $22.00 price target on Evolent Health and gave the stock a “buy” rating in a report on Tuesday, February 13th. Wells Fargo decreased their price target on Evolent Health from $27.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Canaccord Genuity decreased their price target on Evolent Health from $27.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a report on Thursday, March 8th. Finally, ValuEngine downgraded Evolent Health from a “sell” rating to a “strong sell” rating in a report on Monday, April 2nd.

How to Become a New Pot Stock Millionaire

Evolent Health stock traded up $0.70 during trading hours on Thursday, reaching $16.50. 598,806 shares of the company’s stock were exchanged, compared to its average volume of 860,808. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 0.12. Evolent Health has a twelve month low of $10.30 and a twelve month high of $27.50. The company has a market cap of $1,215.76, a P/E ratio of -23.57 and a beta of 1.07.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, February 27th. The technology company reported ($0.10) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.10). Evolent Health had a negative return on equity of 3.51% and a negative net margin of 14.05%. The firm had revenue of $113.97 million during the quarter, compared to the consensus estimate of $111.09 million. equities research analysts forecast that Evolent Health will post -0.34 EPS for the current fiscal year.

In other news, Director Unitedhealth Group Inc sold 3,040,000 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $13.70, for a total value of $41,648,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 8.79% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Grandeur Peak Global Advisors LLC boosted its stake in Evolent Health by 52.9% during the 4th quarter. Grandeur Peak Global Advisors LLC now owns 30,000 shares of the technology company’s stock valued at $369,000 after purchasing an additional 10,375 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in Evolent Health during the 4th quarter valued at about $306,000. Macquarie Group Ltd. boosted its stake in Evolent Health by 44.7% during the 4th quarter. Macquarie Group Ltd. now owns 176,012 shares of the technology company’s stock valued at $2,165,000 after purchasing an additional 54,370 shares during the last quarter. Jane Street Group LLC acquired a new position in Evolent Health during the 4th quarter valued at about $144,000. Finally, Millennium Management LLC boosted its stake in Evolent Health by 61.6% during the 4th quarter. Millennium Management LLC now owns 2,816,786 shares of the technology company’s stock valued at $34,646,000 after purchasing an additional 1,073,282 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Evolent Health (EVH) Given Consensus Rating of “Buy” by Analysts” was published by Zolmax and is owned by of Zolmax. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://zolmax.com/investing/evolent-health-evh-given-consensus-rating-of-buy-by-analysts/2112430.html.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Brokerages Expect PepsiCo  Will Announce Quarterly Sales of $12.42 Billion
Zacks: Brokerages Expect PepsiCo Will Announce Quarterly Sales of $12.42 Billion
Evolent Health  Given Consensus Rating of “Buy” by Analysts
Evolent Health Given Consensus Rating of “Buy” by Analysts
Luxottica Group  and The Cooper Companies  Critical Comparison
Luxottica Group and The Cooper Companies Critical Comparison
Critical Contrast: Axon Enterprise  versus American Outdoor Brands
Critical Contrast: Axon Enterprise versus American Outdoor Brands
Head to Head Analysis: AgroFresh Solutions  & ConvergeOne
Head to Head Analysis: AgroFresh Solutions & ConvergeOne
Leadcoin Price Up 16.3% Over Last Week
Leadcoin Price Up 16.3% Over Last Week


Leave a Reply

 
© 2006-2018 Zolmax.